CN1241942C - 使用胰岛素的肽类似物治疗糖尿病的方法 - Google Patents

使用胰岛素的肽类似物治疗糖尿病的方法 Download PDF

Info

Publication number
CN1241942C
CN1241942C CNB998042765A CN99804276A CN1241942C CN 1241942 C CN1241942 C CN 1241942C CN B998042765 A CNB998042765 A CN B998042765A CN 99804276 A CN99804276 A CN 99804276A CN 1241942 C CN1241942 C CN 1241942C
Authority
CN
China
Prior art keywords
peptide analogs
chain
residue
peptide
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998042765A
Other languages
English (en)
Chinese (zh)
Other versions
CN1294597A (zh
Inventor
A·高尔
N·凌
P·J·康伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN1294597A publication Critical patent/CN1294597A/zh
Application granted granted Critical
Publication of CN1241942C publication Critical patent/CN1241942C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB998042765A 1998-02-23 1999-02-23 使用胰岛素的肽类似物治疗糖尿病的方法 Expired - Fee Related CN1241942C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
US09/028,156 1998-02-23

Publications (2)

Publication Number Publication Date
CN1294597A CN1294597A (zh) 2001-05-09
CN1241942C true CN1241942C (zh) 2006-02-15

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998042765A Expired - Fee Related CN1241942C (zh) 1998-02-23 1999-02-23 使用胰岛素的肽类似物治疗糖尿病的方法

Country Status (20)

Country Link
US (1) US6197926B1 (cg-RX-API-DMAC7.html)
EP (1) EP1056776A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002504491A (cg-RX-API-DMAC7.html)
KR (1) KR20010041238A (cg-RX-API-DMAC7.html)
CN (1) CN1241942C (cg-RX-API-DMAC7.html)
AP (1) AP2000001888A0 (cg-RX-API-DMAC7.html)
AU (1) AU741037B2 (cg-RX-API-DMAC7.html)
BR (1) BR9908178A (cg-RX-API-DMAC7.html)
CA (1) CA2321929A1 (cg-RX-API-DMAC7.html)
EA (1) EA003944B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0100928A3 (cg-RX-API-DMAC7.html)
ID (1) ID26788A (cg-RX-API-DMAC7.html)
IL (1) IL137904A0 (cg-RX-API-DMAC7.html)
NO (1) NO20004198L (cg-RX-API-DMAC7.html)
NZ (1) NZ506447A (cg-RX-API-DMAC7.html)
OA (1) OA11453A (cg-RX-API-DMAC7.html)
PL (1) PL342517A1 (cg-RX-API-DMAC7.html)
SK (1) SK12412000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200003048T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999042482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
CA2408935A1 (en) * 2000-05-12 2001-11-15 Halina Offner Method of treating immune pathologies with low dose estrogen
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
ZA200502613B (en) 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
WO2004110373A2 (en) * 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US8481485B2 (en) * 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US12370251B2 (en) 2009-11-05 2025-07-29 Mercia Pharma, Inc. Adjuvanted nanoparticulate influenza vaccine
CA2780043C (en) 2009-11-13 2019-01-29 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
AU6299596A (en) * 1995-06-30 1997-02-05 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Also Published As

Publication number Publication date
AU741037B2 (en) 2001-11-22
EP1056776A1 (en) 2000-12-06
TR200003048T2 (tr) 2000-12-21
SK12412000A3 (sk) 2002-05-09
HUP0100928A2 (hu) 2001-08-28
JP2002504491A (ja) 2002-02-12
EA003944B1 (ru) 2003-10-30
ID26788A (id) 2001-02-08
OA11453A (en) 2003-12-08
NZ506447A (en) 2002-11-26
BR9908178A (pt) 2002-01-15
NO20004198D0 (no) 2000-08-22
WO1999042482A1 (en) 1999-08-26
IL137904A0 (en) 2001-10-31
US6197926B1 (en) 2001-03-06
EA200000872A1 (ru) 2001-02-26
AP2000001888A0 (en) 2000-09-30
AU2783199A (en) 1999-09-06
PL342517A1 (en) 2001-06-18
CN1294597A (zh) 2001-05-09
CA2321929A1 (en) 1999-08-26
HUP0100928A3 (en) 2001-11-28
KR20010041238A (ko) 2001-05-15
NO20004198L (no) 2000-10-20

Similar Documents

Publication Publication Date Title
CN1241942C (zh) 使用胰岛素的肽类似物治疗糖尿病的方法
JP6552106B2 (ja) 糖尿病を処置するためのモダリティの組み合わせ
US20060034864A1 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CN1188485A (zh) 胰高血糖素样肽-2及其治疗应用
CN1129224A (zh) 类胰高血糖素促胰岛素的多肽类似物组合物及其使用方法
HUT77047A (hu) Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
CN1625564A (zh) 来源于髓鞘碱性蛋白的耐受原性肽
CN107530404A (zh) 1型糖尿病自身免疫的免疫调节治疗
KR20150005904A (ko) 강력한 작용제 효과를 지닌 신규한 ｇｈ-ｒｈ 유사체
EP1093464A2 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CN1124283C (zh) 一种肽、一种支气管扩张剂,和一种血流促进剂
CN1230195A (zh) 免疫定向治疗
AU2605097A (en) Cyclic peptide vaccines for treatment and prevention of diabetes
US6562942B1 (en) Methods for treatment of diabetes using peptide analogues of insulin
CN1379786A (zh) 用于免疫治疗的修饰肽和肽类似物
HUP0000836A2 (hu) Kollagén II-re specifikus T-sejt epitópot tartalmazó peptidek
AU781405B2 (en) Methods for treatment of diabetes using peptide analogues of insulin
EP4081531B1 (en) A composition comprising s-arrestin peptides
CZ20003065A3 (cs) Peptidové analogy insulinu a jejich využití pro léčení diabetes mellitus
JP2000229997A (ja) 環状ペプチド及びエイズワクチン
CN1329922A (zh) C肽联合胰岛素治疗糖尿病并发症及c肽专一性抗体
MXPA00008268A (en) Methods for treatment of diabetes using peptide analogues of insulin
HK1022920A (en) Immune direction therapy

Legal Events

Date Code Title Description
BB1A Publication of application
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee